Estrigenix Therapeutics co-founders Dr. Karyn Frick of UW-Milwaukee
and Dr. Daniel Sem of Concordia University
presented their research findings to an engaged audience at the UW-Milwaukee Innovation Accelerator on May 9. The discussion provided an overview of risks associated with current hormone therapies, and the long-term cognitive vulnerabilities associated with hormone declines in menopause.
The Estrigenix-patented solution seeks to address symptoms associated with menopause, such as hot flashes, but is also studying the long-term impact on dementia and memory decline in post-menopausal women.
The speakers noted that estimates project a $28 billion market for hormone therapies by 2022, and a similar market for Alzheimer’s therapy by 2026. On average, 27 million women experience menopause each year in the U.S. While 80% experience adverse symptoms, only half receive therapeutic treatment during menopause, largely due to concerns about the associated risks.
The forum also highlighted the benefits and proactive, collaborative efforts to “cross fertilize” talent and research in the Milwaukee area.
Information about future WHBF Innovation Network Luncheons is available here
. For more information about the WHBF, contact WHA Vice President of Public Policy Lisa Ellinger